🇺🇸 FDA
Pipeline program

JY231 Injection

JY-CT-25-008

Unknown small_molecule active

Quick answer

JY231 Injection for B-cell Malignancies is a Unknown program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
B-cell Malignancies
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials